Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Natural Rise in Social Security Spending to Be Curbed to 500 Billion Yen
December 20, 2016
- Govt Clarifies Its Goals in Healthcare R&D Plan, Aims to Begin Clinical Trials for iPS-Based Therapies by 2020
December 19, 2016
- Chuikyo Kicks Off Debates on 2018 Dual Reform of Healthcare and Long-Term Care Insurance
December 15, 2016
- HIV Med Descovy OK’ed for NHI Price Listing on Dec. 21
December 15, 2016
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
- MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
- Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
December 14, 2016
- Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
- LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
December 13, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
December 13, 2016
- Balance between Survey Costs and Price Gap Important, Shiozaki Says on Annual Revisions
December 12, 2016
- HIV Med Descovy Approved in Japan
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
- Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
- Health Minister Calls for Structural Change in Pharma Industry
December 12, 2016
- The Sooner the Better, Suga Says on Drug Pricing Revamp
December 12, 2016
- Industry’s “No” to Disclosure of Manufacturing Costs Draws Fire from Chuikyo Reps
December 12, 2016
- (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…